Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The strict control of Spi expression
2021-11-09

The strict control of Spi1 expression is critical for proper myeloid cell fate determination, and genetic or epigenetic changes in the Spi1 gene frequently contribute to the leukemogenesis in mice and human. It is has been shown that Spi1 expression is frequently downregulated in human AML patients
-
SCH is a H R receptor
2021-11-09

SCH-497079 is a H3R receptor antagonist introduced by Schering-Plough, without any publicized pharmacological and structural information. A Phase II clinical trial assessment of SCH-497079 on weight has been completed in a multicenter, randomized, parallel-group and placebo-controlled study in obese
-
A second H R antagonist with benzamide based structure from
2021-11-09

A second H3R antagonist with benzamide-based structure from Johnson & Johnson is JNJ-31001074, known as Bavisant and under chemical IUPAC name of (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone. It is a compound with molecular weight 329.44, HBA four, and MLogP 1.52 encompass
-
In summary we have designed and explored synthetic routes
2021-11-08

In summary, we have designed and explored synthetic routes towards novel acylsulfamoyl benzoxaborole-based HCV NS3 protease inhibitors. Interestingly, the resulting, unoptimized P1–P3 and P2–P4 macrocyclic inhibitors were equipotent in an enzyme assay and somewhat less potent in replicon assays, com
-
The LOD and linear range of the cobas HBV
2021-11-08

The LOD and linear range of the cobas HBV test using the cobas 4800 system in this study were similar to those provided by the manufacturer. We found a strong correlation between the results of the cobas HBV test and CAP/CTM v2.0 systems; however, 7.7% of samples yielded detectable results only with
-
Historically pharmacological investigations have been carrie
2021-11-08

Historically, pharmacological investigations have been carried out by first identifying a biological response to a ligand, and then subsequently using that ligand to identify the receptor(s) responsible for the response (Wilson et al., 1998). However, this approach needed revision with the discovery
-
FOLE was recently approved for use in PN dependent patients
2021-11-08

FOLE was recently approved for use in PN-dependent patients in the United States. However, potential adverse effects of FOLE, including bleeding risk, and effects on the immune system [8], [39], render its use in certain patient populations controversial. Identification of key downstream modulators
-
In this review we aim to provide a comprehensive understandi
2021-11-08

In this review, we aim to provide a comprehensive understanding of: 1) how AT-resident CD4+ T cell subpopulations regulate the metabolic status of AT; and 2) how adipocytes as antigen presenting cells to modulate the activities of CD4+ T cell subpopulations in AT. Under condition with obesity, ad
-
Patient characteristics are presented in
2021-11-08

Patient characteristics are presented in . Serum oestradiol levels on the day of oocyte retrieval or warming were higher in group A (253.2 pg/ml) compared with group B (192.6 pg/ml), despite a significantly reduced number of days (mean 3.5 days) taking oestrogens without the addition of progesterone
-
In summary we discovered azaindole substituted hydroxypyrido
2021-11-08

In summary, we discovered 7-azaindole substituted -hydroxypyridone as a potent zinc-binding GLO1 inhibitor (IC=11nM) through lead generation from HTS and structure-based inhibitor design. The X-ray cocrystal structure and the comparison of binding energies with the indole counterpart revealed that
-
Molecular dynamics studies have proved an effective means
2021-11-08

Molecular dynamics studies have proved an effective means of characterising transition state pathways between the inward- and outward-facing states, and providing the relative propensity for each state. For example, long-timescale simulations of the membrane-embedded LeuT dimer, totalling ∼21 μs, ha
-
The ester moiety is a promising structural
2021-11-08

The ester moiety is a promising structural motif at the C-3 position for the development of drug-like molecules. However, the labile C-3 ester bond impels these derivate to be susceptible to plasmatic degradation by esterases and this is natural steroidal metabolic process [39,40]. Hence, the isoste
-
In the absence of HH ligand HH signaling is actively
2021-11-08

In the absence of HH ligand, HH signaling is actively maintained in a repressed state by the activity of the HH receptor Patched (PTCH). PTCH is a 12-transmembrane domain protein whose intracellular localization is concentrated at the cmv virus of the primary cilium, a single antenna-like structure
-
Many studies support that Gli transcription
2021-11-08

Many studies support that Gli transcription factors are not solely regulated by Hh/smo signaling but are also influenced by crosstalk with other pathways, such as RAS, PI3K/AKT, transforming growth factor-b/SMAD, PKC, or extracellular signal-regulated kinase pathways which are downstream and indepen
-
The findings in mice were echoed in the human
2021-11-08

The findings in mice were echoed in the human studies, in which the effects of higher doses of LY3298178 caused greater weight loss than the selective GLP-1RA dulaglutide. In patients with T2DM, LY3298176 demonstrated meaningful weight loss after only four weeks of treatment. This was consistent wit
16305 records 572/1087 page Previous Next First page 上5页 571572573574575 下5页 Last page